Ipamorelin Compounding Pharmacy Quality Red Flags to Avoid

Print or save as PDF

See the public record for Ipamorelin

Red flag 1: A seller that calls it approved

Ipamorelin is a synthetic five-amino-acid peptide that releases growth hormone through the ghrelin/growth-hormone secretagogue receptor rather than the GHRH receptor [5]. It is not a component of any FDA-approved drug and has no US Pharmacopeia monograph [3][5]. Labels reading "FDA-approved ipamorelin," "an FDA-authorized ipamorelin product" or "the approved version" describe something that does not exist.

FDA added ipamorelin acetate to category 2 for compounding by outsourcing facilities on September 29, 2023, and it is still listed on the agency page dated 04/22/2026 [1][2]. For state-licensed pharmacies it appears only in the nominated-but-withdrawn table, and FDA's category 1 policy does not apply [1][7].

Red flag 2: Committee votes and trial results turned into evidence

On October 29, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on ipamorelin free base and the same tally on ipamorelin acetate, citing a lack of information supporting safety and efficacy [4]. The one published phase 2 study analyzed 114 adults after bowel resection: median time to first tolerated solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, p=0.15, not significant [6].

Red flag 3: A subcutaneous dosing chart

No FDA-approved dose exists. Published human studies used intravenous dosing: 0.03 mg/kg twice daily from postoperative day 1 to 7 or discharge in the ileus trial, and single 15-minute infusions of 4.21 to 140.45 nmol/kg in volunteers [6][8]. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [3].

Red flag 4: Selective, so there are no side effects

In that trial, low potassium occurred in 12.5% on ipamorelin versus 3.4% on placebo, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%; two ipamorelin-treated patients died of surgical complications, with the relationship to the drug unclear [3][6]. FDA also expects that stimulating the GH and IGF-1 axis may carry the risks listed on approved growth hormone labels. Like the approved GH stimulator macimorelin, ipamorelin may also prolong the QT interval, and FDA found no data showing it would not [3].

FDA's stated concerns about compounded ipamorelin

FDA's stated concerns are immunogenicity for certain routes from aggregation and peptide-related impurities, unnatural amino acids that complicate characterization, and a published study reporting serious adverse events including death with intravenous use for gastric motility [1].